Eli Lilly & Co. sought to revoke a patent held by a Johnson & Johnson unit, arguing at a London court it might delay availability of a potential treatment for Alzheimer’s. Both companies have drugs in development that use antibodies to target the build-up of plaque in patients’ brains. Lilly argues its treatment, solanezumab, doesn’t infringe a patent held by J&J’s Janssen Alzheimer Immunotherapy Research & Development LLC, according to court documents. Read the full story.